The Management of Perioperative Immunosuppressant Medications for Rheumatoid Arthritis During Elective Hand Surgery by Klifto, Kevin M et al.
RESEARCH POSTER PRESENTATION DESIGN © 2015
www.PosterPresentations.com
Purpose: Rheumatoid arthritis (RA) is a destructive inflammatory disease that 
commonly involves joints of the hand and wrist. Different recommendations 
exist for continuing or discontinuing immunosuppressant medications during 
the perioperative time period. The purpose of our study was to determine if 
continuing steroids, non-biologic DMARDs, and/or biologic DMARDs were 
associated with an increased risk of postoperative complications.
Methods: We performed a single-centered, retrospective review of a 
consecutive cohort of RA patients who had elective hand surgery by a single 
surgeon. Patients were included if they had a documented diagnosis of 
seropositive RA by a rheumatologist, and had elective hand surgery and/or 
disease-related surgical procedure involving the upper extremity from January 
2008 to August 2018. We stratified patients into different groups for 
comparison by classes of immunosuppressant medications for managing RA. 
These classes included corticosteroids, non-biological DMARDs, biologic 
DMARDs, and/or no medications. Groups were then compared for the 
incidence of postoperative complications. 
Results: Eighty-eight consecutive patients had elective hand and/or upper 
extremity surgeries for RA. Mean patient age at the time of surgery (±SD) 
was 55±13 years (range: 24 to 74 years). Of these 88 patients, eight (9%) 
overall complications occurred. Complications were wound healing failures, 
(n=5, 6%), tendon rupture, (n=1, 1%), hematoma, (n=1, 1%), and surgical site 
infection, (n=1, 1%). Perioperative medications included steroids (n=31), non-
biologic DMARDs (n=68), and biologic DMARDs (n=5). There were no 
significant findings between patients on perioperative corticosteroids, non-
biologic DMARDs, and/or biologic DMARDs and the incidence of 
complications. Mean follow-up was 69±65 weeks (range: 8 to 296 weeks).
Conclusions: Patients with RA who continued corticosteroids, non-biologic 
DMARDs, and/or biologic DMARDS within one dosing interval of their usual 
dose were not associated with a higher risk for postoperative complications 
compared to patients discontinuing these medications perioperatively, 




We performed an Institutional Review Board (IRB#00196757) approved 
retrospective medical record review to collect a consecutive cohort of 
rheumatoid arthritis patients who had elective hand surgery by a single 
surgeon at a single institution. The STROBE checklist was followed 
throughout our review.
Study population
Patients were included if they had a documented diagnosis of seropositive 
rheumatoid arthritis by a rheumatologist with an International Classification 
of Diseases (ICD) 9 code of 714.0 or ICD 10 code of M06.9, and had elective 
hand and/or upper extremity surgery between January 2008 to August 2018. 
Diagnosis of rheumatoid arthritis was confirmed by a rheumatologist with the 
2010 American College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) classification criteria.  
We stratified patients into different groups for comparison by classes of 
chronic medications for managing rheumatoid arthritis taken during the 
perioperative period. These classes included corticosteroids, non-biological 
DMARDs, biologic DMARDs, and/or no medications. Biologic DMARDs 
were considered as perioperative medications if the time of surgery was within 
one dosing interval of that individual’s standard medication regimen. Groups 
were then evaluated for the incidence of postoperative complications and 
compared to determine if classes of medications had any association. 
Demographic variables
Patient characteristics are summarized in Table 1. These include: mean age, 
sex, body mass index (BMI), Race, Ethnicity, employment status, smoking 
status (current every day smoker or quit within past 6 months), moderate 
alcohol use (≥ 1 drink a day for women, ≥ 2 drinks a day for men), illicit drug 
use, comorbidities, and chronic medications to manage rheumatoid arthritis.
Outcomes analyzed
Primary outcomes measured were the number of complications evaluated and 
confirmed by a healthcare provider during patient follow-up. Complications 
were wound healing failure, tendon rupture, hematoma, surgical site infection, 
and overall complications. Non-healing wounds or wound healing failure was 
clinically defined as the absence of healthy granulation tissue, presence of 
necrotic and unhealthy tissue in the wound bed, excess exudate and slough, 
lack of blood supply, re-epithelialization failure, persistent pain, recurrent 
breakdown of the wound, or clinical or subclinical infection. Tendon rupture 
was defined as the tendon partially or completely separating from tissue to 
which it was attached, and confirmed with diagnostic imaging. Hematoma 
was defined as a collection of blood within the tissue and confirmed with 
diagnostic imaging. Surgical site infection was defined by the Centers for 
Disease Control and Prevention (CDC) as an infection occurring at the 
surgical site within 30 days of the operation without an implant or within a 
year of the operation with an implant. 19 Overall complications were defined 
as the sum of all complications occurring in a perioperative medication group. 
Statistical analysis
Statistical analysis was performed to compare complications to different 
combinations of perioperative rheumatoid arthritis medications. We used the 
crosstabulation Fisher’s exact test for categorical complication variables based 
on the nonparametric distribution of population data, small sample sizes, and 
disproportionate sizes of comparative groups. Bimodal logistic regression was 
used to compare patient demographic variables to specific complications to 
identify individual predictors for occurrence. 
MATERIAL AND METHODS
Demographics
Table 1 contains our patient demographics. Eighty-eight consecutive patients 
had elective hand and/or upper extremity surgery for seropositive RA over the 
ten-year study period (mean age 55±13, range: 24 to 74 years). Surgical 
procedures were performed on 42 right upper extremities and 46 left upper 
extremities. Fingers were involved in 44 cases, wrists 42 cases, forearms 4 
cases, and the elbow in 10 surgical cases. Combinations included 5 cases 
involving fingers and wrists, 2 forearms and elbows, 2 wrists and elbows, 1 
wrist and forearm, and 3 fingers and elbows. Perioperative medications 
included steroids (n=31), non-biologic DMARDs (n=68), and biologic 
DMARDs (n=5). Biologic DMARDs continued were adalimumab (n=2) 
within two weeks of surgery, abatacept (n=1) within four weeks of surgery, 
and tocilizumab (n=2) within one week of surgery. Mean follow-up was 
69±65 weeks (range: 8 to 296 weeks).  
Wound healing failure
Eight patients developed complications. Five of the eight (63%) complications 
were wound healing failures (Table 2). Of these five, one case occurred in a 
patient taking steroids and non-biologics, one case occurred in a patient taking 
only non-biologics, and three cases occurred in patients on no medications. 
There were no significant increased risks of wound healing failure in patients 
taking steroids, non-biologic DMARDs, and/or biologic DMARDs during the 
perioperative period (p=NS). Following bimodal logistic regression, there 
were no significant positive predictors for wound healing failure among our 
study demographic variables (p=NS).
Tendon rupture
One of the eight (13%) complications was tendon rupture (Table 2). The 
surgery performed preceding was a synovectomy of the left 4th, 5th, and 6th 
extensor compartments, resection of left distal ulna, and suspension of the 
ulnar shaft using a distally based extensor carpi ulnaris tendon. Three months 
following the procedure, magnetic resonance imaging (MRI) confirmed 
rupture of the left extensor tendons of fingers 3, 4, and 5. This one case 
occurred in a patient taking no medications. The patient stated the ruptured 
occurred two months prior from no known inciting event. There were no 
significant increased risks of tendon rupture in patients taking no medications, 
steroids, non-biologic DMARDs, and/or biologic DMARDs during the 
perioperative period (p=NS). Following bimodal logistic regression, there 
were no significant positive predictors for tendon rupture among our study 
demographic variables (p=NS).
Hematoma
One of the eight (13%) complications was a hematoma (Table 2). This one 
case occurred in a patient taking no medications. There were no significant 
increased risks of hematoma in patients taking no medications, steroids, non-
biologic DMARDs, and/or biologic DMARDs during the perioperative period 
(p=NS). Following bimodal logistic regression, there were no significant 
positive predictors for hematoma among our study demographic variables 
(p=NS).
Surgical site infection
One of the eight (13%) complications was a surgical site infection (Table 2). 
This one case occurred in a patient taking steroids and non-biologics (p=NS). 
There were no significant increased risks of surgical site infections in patients 
taking steroids, non-biologic DMARDs, and/or biologic DMARDs during the 
perioperative period. Following bimodal logistic regression, there were no 
significant positive predictors for surgical site infections among our study 
demographic variables (p=NS).
Overall complications
There were eight overall complications in 88 (9%) hand surgery cases (Table 
2). Two (25%) in patients taking steroids and non-biologics, one (25%) in 
patients taking only steroids, and five (63%) in patients taking no medications 
(p=NS). There were no significant increased risks of overall complications in 
patients taking steroids, non-biologic DMARDs, and/or biologic DMARDs 
during the perioperative period. Following bimodal logistic regression, there 
were no significant positive predictors for overall complications among our 
study demographic variables (p=NS). 
RESULTS
CONCLUSION
▪Patients with seropositive 
RA who continued 
corticosteroids, non-
biologic DMARDs, and/or 
biologic DMARDS did not 
have a higher occurrence 
of postoperative 




elective hand surgery. 
There were no associated 
predictors for patients 
developing postoperative 
complications. Our 
findings suggest patients 
with RA may be able to 
continue medications 
during elective hand 
surgery. A prospective 
randomized controlled trial 
should be performed to 
validate our study findings. 
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Rheumatoid arthritis (RA) is the most common chronic destructive 
inflammatory disease.  Synovial surfaces of the hand and wrist joints are 
affected in 70% of patients with RA. 1,2 If untreated, RA progresses to joint 
destruction and pain, disability, systemic complications, poor quality of life, 
and a decreased lifespan. 1 First-line medication management with 
immunosuppressing disease-modifying antirheumatic drugs (DMARDs) has 
proven to improve survival and decrease surgical interventions in patients with 
RA. 1-3 However, these medications prevent disease progression, and do not 
treat already damaged joints. 2,3
As the disease progresses, surgery may be required to decrease pain, correct 
deformities, and increase range of motion. 2,4 Prior to any surgical procedure, 
many surgeons discontinue immunosuppressant medications to prevent the 
complications associated with wound healing and surgical wound infections. 4-
10 Corticosteroids, non-biologic and biologic DMARDs are all classes of 
medications with different pharmacologic mechanisms and varying 
immunosuppressant activity commonly taken by patients diagnosed with 
rheumatoid arthritis to prevent disease progression. 3 Continuing steroids and 
non-biologic DMARDs, but holding biologic DMARDs weeks prior to having 
hip or knee surgery is currently recommended by the American College of 
Rheumatology and American Association of Hip and Knee Surgeons and the 
literature. 1,3,11-14 These recommendations include discontinuing etanerept 
1week before surgery, infliximab, golimumab, tocilizumab, abatacept, 
adalimumab, certolizumab, 4 weeks before surgery, and rituximab 8 weeks 
before surgery. 1,3,11-14
We could find no study in the literature that evaluated different combinations 
of perioperative immunosuppressant medications in a cohort of rheumatoid 
arthritis patients that had elective hand surgery. The primary purpose of our 
study was to determine if continuing steroids, non-biologic DMARDS, and/or 
biologic DMARDS was associated with increased postoperative 
complications. A secondary aim was to see what patient demographic 
variables and comorbidities were associated or predictors for developing 
specific complications in our patient population.
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